Guangzhou LBP Medicine Science & Technology Co., Ltd. (688393.SS)
CNY 19.28
(0.47%)
CNY 19.28
(0.47%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 161.62 Million CNY | -5.17% |
| 2022 | 170.44 Million CNY | 9.29% |
| 2021 | 155.95 Million CNY | 25.1% |
| 2020 | 124.66 Million CNY | 33.57% |
| 2019 | 93.33 Million CNY | 6.97% |
| 2018 | 87.24 Million CNY | 32.64% |
| 2017 | 65.77 Million CNY | 82.31% |
| 2016 | 36.08 Million CNY | 0.0% |
| 2013 | 42.13 Million CNY | 126.55% |
| 2012 | 18.59 Million CNY | -70.63% |
| 2011 | 63.31 Million CNY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q3 | 125.71 Million CNY | 24.7% |
| 2024 Q1 | 116.59 Million CNY | -27.86% |
| 2024 Q2 | 100.81 Million CNY | -13.54% |
| 2023 Q2 | 141.16 Million CNY | -3.95% |
| 2023 Q3 | 142.72 Million CNY | 1.1% |
| 2023 Q1 | 146.97 Million CNY | -13.77% |
| 2023 FY | 161.62 Million CNY | -5.17% |
| 2023 Q4 | 161.62 Million CNY | 13.25% |
| 2022 Q2 | 139.38 Million CNY | -4.72% |
| 2022 Q1 | 146.28 Million CNY | -6.2% |
| 2022 FY | 170.44 Million CNY | 9.29% |
| 2022 Q4 | 170.44 Million CNY | 14.03% |
| 2022 Q3 | 149.47 Million CNY | 7.24% |
| 2021 Q1 | 123 Million CNY | -1.33% |
| 2021 Q3 | 144.63 Million CNY | 7.51% |
| 2021 FY | 155.95 Million CNY | 25.1% |
| 2021 Q4 | 155.95 Million CNY | 7.83% |
| 2021 Q2 | 134.53 Million CNY | 9.37% |
| 2020 Q4 | 124.66 Million CNY | 38.7% |
| 2020 Q2 | 105.32 Million CNY | 62.2% |
| 2020 Q1 | 64.93 Million CNY | -30.42% |
| 2020 FY | 124.66 Million CNY | 33.57% |
| 2020 Q3 | 89.88 Million CNY | -14.66% |
| 2019 Q2 | 95.01 Million CNY | 0.0% |
| 2019 FY | 93.33 Million CNY | 6.97% |
| 2019 Q4 | 93.33 Million CNY | 0.0% |
| 2018 FY | 87.24 Million CNY | 32.64% |
| 2017 FY | 65.77 Million CNY | 82.31% |
| 2016 FY | 36.08 Million CNY | 0.0% |
| 2014 Q3 | 30.53 Million CNY | 0.0% |
| 2013 FY | 42.13 Million CNY | 126.55% |
| 2012 FY | 18.59 Million CNY | -70.63% |
| 2011 FY | 63.31 Million CNY | 0.0% |